Koronavirüs-19’un Kardiyovasküler Sistem Üzerine Etkileri
Yıl: 2020 Cilt: 12 Sayı: 2 Sayfa Aralığı: 305 - 314 Metin Dili: Türkçe DOI: DOI: 10.5336/nurses.2020-75550 İndeks Tarihi: 10-11-2020
Koronavirüs-19’un Kardiyovasküler Sistem Üzerine Etkileri
Öz: İlk olarak 2019 yılının Aralık ayında Çin’in Wuhan kentinde pnömoni semptomları ile başvuran bir grup hastada tanımlanan, vaka sayısı tüm dünyada giderek artan ve Dünya Sağlık Örgütü tarafından pandemi olarak ilan edilen koronavirüs-19’un (COVID-19) kliniği asemptomatik durum ile ölümcül pnömoni arasında değişmektedir. COVID-19, tüm vücut sistemlerini şiddetli düzeyde etkilemektedir. Ayrıca; tablonun yaşlı, kanser tanılı, immün sistemi baskılanmış, hipertansiyon, kronik obstrüktif akciğer hastalığı, astım gibi kronik hastalıkları olan bireylerde daha kötü seyrettiği ve bu bireylerin mortalite için yüksek risk taşıdığı bildirilmektedir. Kronik hastalıkların COVID-19 prognozuna etkisinin yanı sıra COVID-19 enfeksiyonu da mevcut kronik durumların alevlenmesine veya sistemler üzerinde akut ve kronik komplikasyonlara neden olabilmektedir. Tüm dünyayı etkileyen COVID-19 pandemisinde viral enfeksiyonun kardiyovasküler sistem üzerinde akut ve kronik etkileri konusunda daha fazla bilgiye gereksinim duyulduğu ve gelecek araştırmalarda bu konunun ele alınması gerektiğine dikkat çekilmiştir. Bu çalışmanın amacı, ülkemizde gün geçtikçe vaka sayısı ve mortalite oranı artan COVID-19 ve kardiyovasküler hastalık arasındaki ilişki ile COVID-19’un kardiyovasküler sistem üzerine etkileri hakkında bilgi sunmaktır. Ayrıca, semptom yükü oldukça fazla ve organ hasarıyla ilişkili komplikasyon riski yüksek COVID-19 hastalarının bakımında önemli konulara dikkat çekilerek holistik hemşirelik bakımının gelişmesine katkı verilebileceği öngörülmektedir.
Anahtar Kelime: Effects of Coronavirus-19 on the Cardiovascular System
Öz: The clinical prognosis of coronavirus-19 (COVID-19), which was first identified in a group of patients presenting with pneumonia symptoms in Wuhan, China in December 2019, the number of cases is increasing all over the world and declared as a pandemic by the World Health Organization, varies between asymptomatic status and deadly pneumonia. Infection of the COVID-19 strongly affect all body systems. It is emphasized that the prognosis of the virus is worse in elderly, patients with cancer and individuals with chronic diseases such as hypertension, chronic obstructive pulmonary disease and asthma and poses a high risk for mortality. In addition to the effect of chronic diseases on the prognosis of COVID-19, COVID-19 infection may cause exacerbation of existing chronic conditions or acute and chronic complications on systems. COVID-19 pandemic affects the whole world, thus more awareness is needed about the acute and chronic effects of viral infection on the cardiovascular system, and this issue should be addressed in future research. The purpose of this review is to provide information on the relationship between COVID19 and cardiovascular diseases and the effects of COVID-19 on the cardiovascular system. In addition, a holistic approach in nursing care is an important requirement for COVID-19 patients, whose symptom burden and risk of complications associated with organ damage are quite high. This review may contribute to the development of nursing care by taking attention to important issues to be followed in the care of COVID-19 patients.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- Force aDT, Ranieri V, Rubenfeld g, Thompson B, Ferguson N, Caldwell E, et al. acute respiratory distress syndrome: the Berlin definition. JaMa. 2012;307(23):2526-33. [Crossref] [PubMed]
- Rothan Ha, Byrareddy sN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J autoimmun. 2020;10:24-33. [Crossref] [PubMed] [PMC]
- Chan JWM, Ng CK, Chan YH, Mok TYW, Lee s, Chu sYY, et al. short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (saRs). Thorax. 2003;58(8):686-9. [Crossref] [PubMed] [PMC]
- Clerkin KJ, Fried Ja, Raikhelkar J, sayer g, griffin JM, Masoumi a, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation. 2020 Mar 21. Doi: 10.1161/CIRCuLaTIONaHa.120.046941. Online ahead of print. [Crossref] [PubMed]
- Huang C, Wang Y, Li X, Ren L, zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. [Crossref] [PubMed]
- Tan W, aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. Int J Cardiol. 2020;309:70-7. [Crossref] [PubMed] [PMC]
- Wang D, Hu B, Hu C, zhu F, Liu X, zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JaMa. 2020;323(11):1061-9. [Crossref] [PubMed] [PMC]
- Badawi a, Ryoo sg. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERs-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2016;49:129-33. [Crossref] [PubMed] [PMC]
- Hui Ds, azhar EI, Madani Ta, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health: the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264-6. [Crossref] [PubMed] [PMC]
- 10. Cui J, Li F, shi zL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181-92. [Crossref] [PubMed] [PMC]
- 11. Rodriguez-Morales aJ, Cardona-Ospina Ja, gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and metaanalysis. Travel Med Infect Dis. 2020;2020:101623. [Crossref] [PubMed] [PMC]
- 12. Wu F, zhao s, Yu B, Chen YM, Wang W, song zg, et al. a new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-9. [PubMed] [PMC] [Crossref]
- 13. guo J, Huang z, Lin L, Lv J. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J am Heart assoc. 2020;9(7):e016219. [Crossref] PubMed]
- 14. Xiong TY, Redwood s, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020;1-3. [PubMed]
- 15. Kirchdoerfer RN, Cottrell Ca, Wang N, Pallesen J, Yassine HM, Turner HL, et al. Pre-fusion structure of a human coronavirus spike protein. Nature. 2016;531(7592):118-21. [Crossref] [PubMed] [PMC]
- 16. Lei J, Li J, Li X, Qi X. CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 2020;295(1):18. [Crossref] [PubMed]
- 17. Choi KR, Jeffers Ks, Logsdon MC. Nursing and the novel coronavirus: risks and responsibilities in a global outbreak. J adv Nurs. 2020;1-2. [Crossref] [PubMed] [PMC]
- 18. Lee N, Hui D, Wu a, Chan P, Cameron P, Joynt gM, et al. a major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl Med. 2003;348(20):1986-94. [Crossref] [PubMed]
- 19. Khan a, Benthin C, zeno B, albertson TE, Boyd J, Christie JD, et al. a pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21(1):234. [Crossref] [PubMed] [PMC]
- 20. golubev a, Moroz V, sundukov D. Pathogenesis of acute respiratory distress syndrome. general Reanimatology. 2012;8(4):13. [Crossref]
- 21. Dong L, Hu s, gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60. [Crossref] [PubMed]
- 22. Li B, Yang J, zhao F, zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531-8. [Crossref] [PubMed] [PMC]
- 23. Wu z, Mcgoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JaMa. 2020;323(13):1239-42. [Crossref] [PubMed]
- 24. Porcheddu R, serra C, Kelvin D, Kelvin N, Rubino s. similarity in case fatality rates (CFR) of COVID-19/saRs-COV-2 in Italy and China. J Infect Dev Ctries. 2020;14(02):125-8. [Crossref] [PubMed]
- 25. guo T, Fan Y, Chen M, Wu X, zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JaMa Cardiol. 2020; e201017. [Crossref] [PubMed] [PMC]
- 26. zheng YY, Ma YT, zhang JY, Xie X. COVID19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259-60. [Crossref] [PubMed] [PMC] 27. Corrales-Medina VF, alvarez KN, Weissfeld La, angus DC, Chirinos Ja, Chang CC, et al. association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JaMa. 2015;313:264-74. [Crossref] [PubMed] [PMC]
- 28. Murthy s, gomersall CD, Fowler Ra. Care for critically ill patients with COVID-19. JaMa. 2020 Mar 11. Doi: 10.1001/jama.2020.3633. Online ahead of print. [Crossref] [PubMed]
- 29. zeng J, Huang J, Pan L. How to balance acute myocardial infarction and COVID-19: the protocols from sichuan Provincial People’s Hospital. Intensive Care Med. 2020;1-3. [Crossref] [PubMed]
- 30. Liu Y, Yang Y, zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019 -nCoV infected patients linked to viral loads and lung injury. sci China Life sci. 2020;63(3):364-74. [Crossref] [PubMed] [PMC]
- 31. zhang H, Baker a. Recombinant human aCE2: acing out angiotensin II in aRDs therapy. Crit Care. 2017;21(1):305. [Crossref] [PubMed] [PMC]
- 32. Thygesen K, alpert Js, Jaffe as, Chaitman BR, Bax JJ, Morrow Da, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237-69. [Crossref]
- 33. aktoz M, altay H, aslanger E, atalar E, aytekin V, Baykan Oa, et al. [Turkish Cardiology association consensus report: Covid-19 pandemic and cardiovascular diseases]. Turk Kardiyol Dern ars. 2020;48 suppl 1:1-48.
- 34. Dursunoğlu D, Dursunoğlu N. [Inflammation endothelial dysfunction, cardiovascular biomarkers and sleep disordered breathing]. Turkiye Klinikleri Cardiol-special Topics. 2018;11(1):47-53.
- 35. alhazzani W, Møller MH, arabi YM, Loeb M, gong MN, Fan E, et al. surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020;1-34. [Crossref] [PubMed] [PMC]
- 36. guan WJ, Ni zY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Feb 28. Doi: 10.1056/NEJMoa2002032. Online ahead of print. [Crossref] [PubMed] [PMC]
- 37. zhou F, Yu T, Du R, Fan g, Liu Y, Liu z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(102299):1054-62. [Crossref]
- 38. Witt DM, Nieuwlaat R, Clark NP, ansell J, Holbrook a, skov J, et al. american society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood adv. 2018;2(22):3257-91. [Crossref] [PubMed] [PMC]
- 39. Itkonen MK, Tornio a, Lapatto-Reiniluoto O, Neuvonen M, Neuvonen PJ, Niemi M, et al. Clopidogrel increases dasabuvir exposure with or without ritonavir, and ritonavir inhibits the bioactivation of clopidogrel. Clin Pharmacol Ther. 2019;105(1):219-28. [Crossref] [PubMed] [PMC]
- 40. Ma J, Hu F, sun HM, Chen J, Ding XB, Li J. Nursing experience of treating a critical ill patient with novel coronavirus (2019-nCoV) infected pneumonia by using ECMO. J New Med. 2020;30:74-7.
| APA | GULBAHAR EREN M (2020). Koronavirüs-19’un Kardiyovasküler Sistem Üzerine Etkileri. , 305 - 314. DOI: 10.5336/nurses.2020-75550 |
| Chicago | GULBAHAR EREN Merve Koronavirüs-19’un Kardiyovasküler Sistem Üzerine Etkileri. (2020): 305 - 314. DOI: 10.5336/nurses.2020-75550 |
| MLA | GULBAHAR EREN Merve Koronavirüs-19’un Kardiyovasküler Sistem Üzerine Etkileri. , 2020, ss.305 - 314. DOI: 10.5336/nurses.2020-75550 |
| AMA | GULBAHAR EREN M Koronavirüs-19’un Kardiyovasküler Sistem Üzerine Etkileri. . 2020; 305 - 314. DOI: 10.5336/nurses.2020-75550 |
| Vancouver | GULBAHAR EREN M Koronavirüs-19’un Kardiyovasküler Sistem Üzerine Etkileri. . 2020; 305 - 314. DOI: 10.5336/nurses.2020-75550 |
| IEEE | GULBAHAR EREN M "Koronavirüs-19’un Kardiyovasküler Sistem Üzerine Etkileri." , ss.305 - 314, 2020. DOI: 10.5336/nurses.2020-75550 |
| ISNAD | GULBAHAR EREN, Merve. "Koronavirüs-19’un Kardiyovasküler Sistem Üzerine Etkileri". (2020), 305-314. https://doi.org/DOI: 10.5336/nurses.2020-75550 |
| APA | GULBAHAR EREN M (2020). Koronavirüs-19’un Kardiyovasküler Sistem Üzerine Etkileri. Türkiye Klinikleri Hemşirelik Bilimleri Dergisi, 12(2), 305 - 314. DOI: 10.5336/nurses.2020-75550 |
| Chicago | GULBAHAR EREN Merve Koronavirüs-19’un Kardiyovasküler Sistem Üzerine Etkileri. Türkiye Klinikleri Hemşirelik Bilimleri Dergisi 12, no.2 (2020): 305 - 314. DOI: 10.5336/nurses.2020-75550 |
| MLA | GULBAHAR EREN Merve Koronavirüs-19’un Kardiyovasküler Sistem Üzerine Etkileri. Türkiye Klinikleri Hemşirelik Bilimleri Dergisi, vol.12, no.2, 2020, ss.305 - 314. DOI: 10.5336/nurses.2020-75550 |
| AMA | GULBAHAR EREN M Koronavirüs-19’un Kardiyovasküler Sistem Üzerine Etkileri. Türkiye Klinikleri Hemşirelik Bilimleri Dergisi. 2020; 12(2): 305 - 314. DOI: 10.5336/nurses.2020-75550 |
| Vancouver | GULBAHAR EREN M Koronavirüs-19’un Kardiyovasküler Sistem Üzerine Etkileri. Türkiye Klinikleri Hemşirelik Bilimleri Dergisi. 2020; 12(2): 305 - 314. DOI: 10.5336/nurses.2020-75550 |
| IEEE | GULBAHAR EREN M "Koronavirüs-19’un Kardiyovasküler Sistem Üzerine Etkileri." Türkiye Klinikleri Hemşirelik Bilimleri Dergisi, 12, ss.305 - 314, 2020. DOI: 10.5336/nurses.2020-75550 |
| ISNAD | GULBAHAR EREN, Merve. "Koronavirüs-19’un Kardiyovasküler Sistem Üzerine Etkileri". Türkiye Klinikleri Hemşirelik Bilimleri Dergisi 12/2 (2020), 305-314. https://doi.org/DOI: 10.5336/nurses.2020-75550 |
